Navigation Links
Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress
Date:5/21/2012

NEW YORK, May 21, 2012 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that an abstract highlighting the dose related increases in iron storage parameters as observed in prior clinical trials of Zerenex™ (ferric citrate), has been accepted for poster presentation at the upcoming 49th ERA-EDTA (European Renal Association – European Dialysis and Transplant Association) Congress, taking place May 24-27, 2012, in Paris, France.

The following poster will be presented on Saturday, May 26, 2012, from 9:30am to 10:45am local time:

  • A Meta-Analysis of Ferric Citrate for Hyperphosphatemia: The Effects of an Oral Iron-Containing Phosphate Binder on Serum Ferritin and Saturated Transferrin in Hemodialysis Patients (Abstract # SAP534)

Zerenex, the Company's oral, ferric iron-based drug candidate for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis, is currently in Phase 3 clinical development pursuant to a Special Protocol Assessment (SPA) agreement with the FDA.  The Zerenex Phase 3 registration program is comprised of an already completed Phase 3 short-term study, and an ongoing Phase 3 long-term study.

The above referenced abstract is available for viewing on-line at http://www.m-events.com/customer/2012/era-edta/data/12575.pdf.

Keryx holds a worldwide license (except for certain Asian Pacific countries) to Zerenex (ferric citrate) from Panion & BF Biotech, Inc. The Japanese rights are sublicensed by Keryx to Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for th
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Takeda Pharmaceutical Company Limited ("Takeda") today announced ... of data from a 10-year epidemiology study to ... (U.S.) Food and Drug Administration (FDA), ... Ministry of Health, Labour, and Welfare (MHLW) / ... for pioglitazone containing medicines, including ACTOS (pioglitazone HCl). ...
(Date:8/28/2014)...  In anticipation of the upcoming MEDevice San Diego ... the first time. Industry Overview: Medtech & Life Sciences ... snapshot of San Diego,s critical involvement ... latest employment statistics to current venture capital investment trends, the ... such a vital part of the global medical device ...
(Date:8/28/2014)... 28, 2014 /PRNewswire-iReach/ -- Academy Leadership, an elite leadership ... has published a case study highlighting one ... Course . In September and October 2014, Academy Leadership ... Albuquerque , Indianapolis , Salt Lake ... - http://photos.prnewswire.com/prnh/20140828/140814 Leadership training ...
Breaking Medicine Technology:Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 2Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 3Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 4Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 5Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 6New Infographic Published - Overview of Medtech & Life Sciences Industry in San Diego 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 3Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 4Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 5
... SEATTLE, Aug. 22 Vical Incorporated (Nasdaq:,VICL) announced ... vaccine Phase 2a,clinical trials, using a plasmid DNA ... and manufactured by Vical, reinforced previously,reported Phase 1 ... was safe and well-tolerated, and was effective in ...
... - Alfacell Corporation,(Nasdaq: ACEL ) today announced ... Oncology (2007; Vol. 31, Issue 3: 663-669) reports ... cell types and tumor cell lines. The observed ... cytotoxic effect on cancer cells and,mechanistic synergism with ...
Cached Medicine Technology:Multiple NIH Phase 2 HIV Vaccine Trials Using Vical's Technology Produce Encouraging Results 2Multiple NIH Phase 2 HIV Vaccine Trials Using Vical's Technology Produce Encouraging Results 3Paper in International Journal of Oncology Reports Alfacell's ONCONASE(R) Suppresses Intracellular Oxidative Stress 2Paper in International Journal of Oncology Reports Alfacell's ONCONASE(R) Suppresses Intracellular Oxidative Stress 3
(Date:8/29/2014)... RBS Reputation Management has brought a new ... service is to help those individuals and organizations that are ... Book. The service would push down the ranking of Scam ... fully invisible on Google. , RBS Reputation Management provides ... asked how company can provide guarantee of results with the ...
(Date:8/29/2014)... August 29, 2014 Los Angeles ... offering mini implants to area patients. With this treatment, ... of long-term teeth shifting and loss of appearance. Although ... dental implants , their smaller size allows for ... and easier recovery. Once placed, mini implants can be ...
(Date:8/29/2014)... 2014 "After reading a study that said ... often, I decided that there needed to be a way ... said a concerned inventor from Sikestons, Mo. , The Stand ... It builds endurance and keeps the user from sitting too ... use and producible in design variations, it's ideal for anyone ...
(Date:8/29/2014)... India (PRWEB) August 29, 2014 Ethane ... has recently launched a new service named HTML web ... research based service. Before tailoring the service, Ethane Web ... by other companies. The company has done its best ... impeccable and able to deliver outstanding results to clients. ...
(Date:8/29/2014)... and basic life support (BLS) videos available on ... health guidelines, according to a new study published ... for the Australasian College for Emergency Medicine (ACEM). ... cardiac arrest are known to improve survival for,victims. ... put together the study, which reviewed educational videos ...
Breaking Medicine News(10 mins):Health News:RBS Reputation Management Announces a New Online Reputation Management Service 2Health News:Dental Implants Dentist, Kevin Sands DDS, Is Now Offering Mini Implants 2Health News:Ethane Web Technologies Launches a New Web Design Service 2
... UC Irvine Medical Center recently received a Silver Medal of ... for its role in supporting organ and tissue donation. ... the highest-performing 12-month period between Oct. 1, 2008, and March ... commended in the seven-county Greater Los Angeles area served by ...
... THURSDAY, Dec. 2 (HealthDay News) -- The suicide rate among ... than among civilian women, a new study has found. ... between 2004 and 2007. In the 18-to-34 age group, there ... 33,257,362 nonveterans. That suicide rate amounted to one out ...
... arthritis drug reduces the incidence of non-melanoma skin cancers ... to a study published this week in the ... COX-2 inhibitor celecoxib (brand name Celebrex), which is currently ... acute pain in adults led to a 62 percent ...
... a lawyer, a politician, a professional athlete, an environmentalist or ... some researchers. Still others say the driving force is our ... But a new child-development theory bridges those two models, says ... Holden,s theory holds that the way a child turns out ...
... early in life led to an accumulation of abdominal fat and ... according to new research. Animals exposed to the fine-particulate air ... and higher blood sugar levels than did animals eating the same ... the polluted air for six hours a day, five days a ...
... From microscopy to computer tomography (CT) scans, imaging ... research, but obtaining high-quality images often requires advanced ... a project which launches its preparatory phase today, ... access to state-of-the-art imaging technologies at all levels ...
Cached Medicine News:Health News:UC Irvine Medical Center is recognized for its commitment to organ donation 2Health News:Female Vets Much More Likely to Commit Suicide, Study Finds 2Health News:Widely used arthritis pill protects against skin cancer 2Health News:Widely used arthritis pill protects against skin cancer 3Health News:Beyond nature vs. nurture: Parental guidance boosts child's strengths, shapes development 2Health News:Beyond nature vs. nurture: Parental guidance boosts child's strengths, shapes development 3Health News:Beyond nature vs. nurture: Parental guidance boosts child's strengths, shapes development 4Health News:Polluted air increases obesity risk in young animals 2Health News:Polluted air increases obesity risk in young animals 3Health News:Better imaging from bench to bedside 2
... fast, precise patternless edge for a perfect ... ALE-X1. The latest advance in lens processing ... and functions. High-speed processing, a diamond luster ... precise three-dimensional frame tracing via the automated ...
... mapping software system enhances clinical evaluations with ... corneal maps. The system offers an enlarged ... refractive and keratometric data, and peripheral keratometric ... subclinical keratoconus as well as pre and ...
... Ergonomic, computer-integrated, flexibility, combined with the ... contemporary styling, make the new Topcon ... highly competitive 21st Century practice environments: ... lane fits comfortably in an 8' ...
... Topcon combines the benefits of IMAGEnet Lite, ... a Compaq PC with the Topcon TRC-NW6 ... use color fundus screening package. The system ... software with Topcons Non-Mydriatic retinal camera allowing ...
Medicine Products: